Neopharma Technologies Limited

Neopharma Technologies Limited is an Australian public unlisted company that specialises in the development of innovative and unique medical devices.

TamperLoks is a unique tamper-proof Drug of Abuse Specimen Collection and Testing Device that comprehensively address issues relating to adulteration, substitution and other forms of tampering in the enforcement of Drug of Abuse screening. TamperLoks effectively addresses the concerns of transparency, corruption, chain of custody and other legal and practical issues within the exercise of Drug of Abuse enforcement.

TamperLoks, Lock Down, Data Vault and Chain of Custody by Neopharma Technologies Limited are a patented system for drugs of abuse testing and enforcement featuring:
• the first three-chamber urine based test device
• 100% tamper-proof and leak-proof
• able to test up to 20 drugs at a time
• fast, reliable, efficient and user-friendly.

Data Vault is an ICT Management System with both iOS and Android mobility applications with the aim of utilising technology to enhance the operational efficiency of the whole Drug of Abuse Testing exercise. This solution will capture information for further utilisation right from the manufacturing stage, logistics, inventory, donor management, testing of urine specimen in the field to confirmation of the results in the laboratory. All this information has the option to be stored on premise or cloud.
The advantages of Data Vault are as follows:
• Improve efficiency by eliminating human intervention
• Tracking TamperLoks right from manufacturing stage to enforcement and confirmatory operations
• Real time basis monitoring
• Makes available accurate reports and documentation
• Flexible and expandable solution to other phases
• Adopting the latest in technology application of RFID tags, 2D barcode, imaging, etc.
• Minimal Standard Operational Procedure (SOP) changes.

Company’s Keywords:

drug testing, urinalysis assay, drug of abuse testing research, design, information systems, integrated systems, presumptive diagnostics, life sciences, medical devices